Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet | PCD Pharma Manufacturer & Supplier India | Trumac Healthcare
Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet
WHO-GMP Manufacturer & PCD Pharma Franchise Supplier in India
Form: Tablet
Class: Third-Gen Cephalosporin + Fourth-Gen Fluoroquinolone
✓ Pan-India Monopoly PCD
✓ 1 Brand Options
Pricing, brochure & monopoly territory within 24 hrs.
Our Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet Brand Options (1 option)
Trumac Healthcare manufactures and supplies the following Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet brands for PCD pharma distribution. Click any brand to view full specifications and packaging.
Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet is manufactured under WHO-GMP-certified conditions by Trumac Healthcare and supplied for PCD/Propaganda-cum-Distribution pharma franchise on monopoly basis across India. Whether you are a PCD distributor, stockist or retail chemist, our Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab formulation comes with full quality assurance, regulatory documentation and reliable pan-India despatch.
Therapeutic Indications
- Severe community-acquired pneumonia
- Complicated intra-abdominal infections (step-down from IV)
- Post-surgical sepsis maintenance therapy
- Severe ENT infections requiring broad coverage
Mechanism of Action
Cefixime binds penicillin-binding proteins (PBP-3) on gram-negative bacteria, inhibiting the final transpeptidation step of peptidoglycan synthesis. The result is bacterial cell wall destabilisation and osmotic lysis. Cefixime is resistant to many beta-lactamases produced by gram-negative organisms — distinguishing it from earlier cephalosporins. Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication. Concentration-dependent killing complements cefixime's time-dependent action.
Dosage & Administration
- Adults: 1 tablet once daily for 5–14 days based on infection severity.
- To be prescribed by physician.
Side Effects
- GI upset, headache, dizziness, photosensitivity.
- Class warnings (moxifloxacin): tendinopathy, QT prolongation, peripheral neuropathy, CNS effects, dysglycaemia, aortic aneurysm risk in elderly.
Contraindications
- Hypersensitivity to cephalosporins.
- Severe penicillin allergy (cross-reactivity ~10%).
- Renal impairment requires dose adjustment.
- History of GI disease (caution).
- Hypersensitivity to fluoroquinolones.
- Pregnancy and lactation.
- Children/adolescents.
- QT prolongation risk.
- Tendon disorder history.
Storage
Store below 30 °C in a dry place, protected from light and moisture.
PCD Pharma Franchise for Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet
- ✓ WHO-GMP certified manufacturing facility
- ✓ Pan-India monopoly distribution rights available
- ✓ Multiple pack sizes: 10 x 10 (Alu Alu)
- ✓ Trade-friendly PTR / PTS margins
- ✓ Free promotional material on request
- ✓ Full DCGI documentation and quality certificates supplied
Trumac Healthcare offers 1 brand option for Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet — each available in different pack sizes with trade-friendly margins. View the brand-specific pages below for detailed specifications, MRPs and packaging options.
For PCD franchise opportunities, monopoly distribution rights, or third-party contract manufacturing of Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet, contact our business development team. WhatsApp +91 9041677932 or email info@trumachealthcare.net.
Frequently Asked Questions
Who is the manufacturer of Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet?
Trumac Healthcare is a WHO-GMP certified manufacturer of Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet in India. We supply our own brand range (see brand options above) and also offer third-party contract manufacturing for PCD distributors.
Is Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet available for PCD pharma franchise on monopoly basis?
Yes. We offer Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet for PCD/Propaganda-cum-Distribution pharma franchise on monopoly basis across all districts of India. Contact our business development team for pricing and territory availability.
What pack sizes are available for Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet?
Available pack sizes include: 10 x 10 (Alu Alu).
What is the MRP / trade price for Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet?
MRPs range from ₹6950 to ₹6950 across our brand variants. Trade-friendly PTR/PTS margins available on request — WhatsApp +91 9041677932 for current rates.
How do I place an order or franchise enquiry?
WhatsApp +91 9041677932 or email info@trumachealthcare.net with your enquiry. Our team will revert within 24 hours with full pricing, brochure and franchise terms.
Ready to start your PCD franchise for Cefixime (400 mg) + Moxifloxacin (400 mg) Extended Release Tab Tablet?